Persistent anti-Gag, -Nef, and -Rev IgM levels as markers of the impaired functions of CD4+ T-helper lymphocytes during SIVmac251 infection of cynomolgus macaques

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 1, 2005, Pages 1-11

  Régulier, Emmanuel G ^a   Panemangalore, Reshma ^a   Richardson, Max W ^a   DeFranco, Jeremy J ^a   Kocieda, Virginia ^a   Gordon Lyles, Devon C ^a   Silvera, Peter ^b   Khalili, Kamel ^a   Zagury, Jean François ^c,d   Lewis, Mark G ^e   Rappaport, Jay ^a  

^a TEMPLE UNIVERSITY   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c INSERM   (France)

^d University of Paris Cité   (France)

^e BIOQUAL INC   (United States)

Author keywords

Antiretroviral therapy; CD4+ Th cells; Cynomolgus macaques; IgM; Isotype switching; SIVmac251

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEF PROTEIN; REV PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HELPER CELL; HUMORAL IMMUNITY; IMMUNE STATUS; LYMPHOCYTE COUNT; MONKEY; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE PRODUCTS, GAG; GENE PRODUCTS, REV; IMMUNOGLOBULINS; LYMPHOCYTE COUNT; MACACA FASCICULARIS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; VIRAL LOAD; VIRAL REGULATORY PROTEINS;

EID: 24144498695     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000173702.05308.c4     Document Type: Article

References (73)

1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981:305:1425-1431.
2. Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV Nature. 1984;312:767-768.
3. Lane HC, Masur H, Edgar LC. et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309:453-458.
4. Miedema F, Petit AJ, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men: HlV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest. 1988;82:1908-1914.
5. Bernstein LJ, Ochs HD, Wedgwood RJ, et al. Defective humoral immunity in pediatric acquired immune deficiency syndrome. J Pediatr. 1985;107:352-357.
6. Rubinstein A, Mizrachi Y, Bernstein L, et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients. AIDS. 2000;14:F55-F62.
7. Fogelman I, Davey V. Ochs HD, et al. Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis. 2000;182:435-441.
8. Shearer GM. HIV-induced immunopathogenesis. Immunity. 1998;9:587-593.
9. Pahwa S, Pahwa R, Saxinger C, et al. Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. Proc Natl Acad Sci USA. 1985;82:8198-8202.
10. Yarchoan R, Redfield RR, Broder S. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders: contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. J Clin Invest. 1986;78:439-447.
11. Schnittman SM, Lane HC, Higgins SE, et al. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science. 1986;233:1084-1086.
12. Martinez-Maza O, Crabb E, Mitsuyasu RT. et al. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol. 1987;138:3720-3724.
13. Mizuma H, Litwin S, Zolla-Pazner S. B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin Exp Immunol. 1988;71:410-416.
14. Ochs HD, Junker AK, Collier AC, et al. Abnormal antibody responses in patients with persistent generalized lymphadenopamy. J Clin Immunol. 1988;8:57-63.
15. Rogers LA, Forster SM, Pinching AJ. IgD production and other lymphocyte functions in HIV infection: immaturity and activation of B cells at different clinical stages. Clin Exp Immunol. 1989;75:7-11.
16. Monroe JG, Silberstein LE. HIV-mediated B-lymphocyte activation and lymphomagenesis. J Clin Immunol. 1995;15:61-68.
17. Eriksson K, Kilander A, Hagberg L, et al. Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals. AIDS. 1995;9:695-700.
18. Ascher MS, Sheppard HW. AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol. 1988;73:165-167.
19. Pahwa SG, Quilop MT, Lange M, et al. Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:757-763.
20. Mizuma H, Zolla-Pazner S, Litwin S, et al. Serum IgD elevation is an early marker of B cell activation during infection with the human immunodeficiency viruses. Clin Exp Immunol. 1987;68:5-14.
21. Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA. 2001;98:10362-10367.
22. Wolthers KC, Otto SA, Lens SM, et al. Functional B cell abnormalities in HIV type 1 infection: role of CD40L and CD70. AIDS Res Hum Retroviruses. 1997;13:1023-1029.
23. Chong Y, Ikematsu H, Kikuchi K, et al. Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2004;20:219-226.
24. De Milito A, Morch C, Sonnerborg A, et al. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS. 2001;15:957-964.
25. Titanji K, Nilsson A, Morch C, et al. Low frequency of plasma nerve-growth factor detection is associated with death of memory B lymphocytes in HIV-1 infection. Clin Exp Immunol. 2003;132:297-303.
26. Nagase H, Agematsu K, Kitano K, et al. Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clin Immunol. 2001;100:250-259.
27. Shirai A, Cosentino M, Leitman-Klinman SF. et al. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest. 1992;89:561-566.
28. Ngo-Giang-Huong N, Candotti D, Goubar A, et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses. 2001;17:1435-1446.
29. Voltersvik P, Albrektsen G, Ulvestad E, et al. Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J Acquir Immune Defic Syndr. 2003;34:358-367.
30. Hirsch VM, Dapolito G, McGann C, et al. Molecular cloning of SIV from sooty mangabey monkeys. J Med Primatol. 1989;18:279-285.
31. Suryanarayana K, Wiltrout TA. Vasquez GM, et al. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res Hum Retroviruses. 1998;14:183-189.
32. Silvera P, Richardson MW, Greenhouse J, et al. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol. 2002;76:3800-3809.
33. Watson A, Ranchalis J, Travis B, et al. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol. 1997;71:284-290.
34. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881-1888.
35. van Asten L, Danisman F, Otto SA, et al. Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS. 2004;18:1885-1893.
36. Cameron PU, Mallal SA, French MA, et al. Major histocompatibility complex genes influence the outcome of HIV infection: ancestral haplotypes with C4 null alleles explain diverse HLA associations. Hum Immunol. 1990;29:282-295.
37. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;2:405-411.
38. Buchbinder SP, Katz MH, Hessol NA, et al. Long-term HIV-1 infection without immunologic progression. AIDS. 1994;8:1123-1128.
39. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995;332:201-208.
40. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333:751-756.
41. Lifson AR, Buchbinder SP, Sheppard HW, et al. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. J Infect Dis. 1991;163:959-965.
42. Phillips AN, Sabin CA, Elford J, et al. CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. AIDS. 1993;7:975-980.
43. Lugada ES, Mermin J, Asjo B, et al. Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway. Scand J Immunol. 2004;59:203-208.
44. Sabin CA, Devereux H, Phillips AN, et al. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS. 1998;12:1347-1352.
45. Leitman SF, Klein HG, Melpolder JJ, et al. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. N Engl J Med. 1989;321:917-924.
46. Moodley D. Coovadia HM, Bobat RA, et al. Age-related pattern of immunoglobulins G, A and M in children born to HIV-seropositive women. Ann Trop Paediatr. 1997;17:83-87.
47. Conge AM, Tarte K, Reynes J. et al. Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. AIDS. 1998;12:1437-1449.
48. Chong Y, Nabeshima S, Furusyo N, et al. Downregulation of CXCR5 in CD27- B cells of HIV-1 infected patients. J Med Virol. 2004;73:362-367.
49. Plaeger S, Bass HZ, Nishanian P. et al. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. Clin Immunol. 1999;90:238-246.
50. Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1993;6:904-912.
51. Liu Y, Wang Z, Rana TM. Visualizing a specific contact in the HIV-1 Tat protein fragment and trans-activation responsive region RNA complex by photocross-linking. J Biol Chem. 1996;271:10391-10396.
52. Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CDS+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83-92.
53. Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:332-340.
54. Froebel KS, Raab GM, D'Alessandro C, et al. A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable. Clin Exp Immunol. 2000;122:72-78.
55. Carbone J, Gil J, Benito JM, et al. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS. 2000;14:2823-2829.
56. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-172.
57. Prince HE, Kleinman S, Czaplicki C, et al. Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J Acquir Immune Defic Syndr. 1990;3:525-530.
58. Fahey JL, Taylor JM, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998;12:1581-1590.
59. Ullum H, Lepri AC, Katzenstein TL, et al. Prognostic value of single measurements of beta-2-microglobulin, immunoglobulin A in HIV disease after controlling for CD4 lymphocyte counts and plasma HIV RNA levels. Scand J Infect Dis. 2000;32:371-376.
60. Atlas A, Thanh Ha TT, Lindstrom A, et al. Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV-1 subtypes A-D. J Med Virol. 2004;72:345-351.
61. O'Gorman MR, DuChateau B, Paniagua M, et al. Abnormal CD40 ligand (CD 154) expression in human immunodeficiency virus-infected children. Clin Diagn Lab Immunol. 2001;8:1104-1109.
62. Chirmule N, Oyaizu N, Kalyanaraman VS, et al. Inhibition of normal B-cell function by human immunodeficiency virus envelope glycoprotein, gp120. Blood. 1992;79:1245-1254.
63. Poudrier J, Weng X, Kay DG, et al. The AIDS disease of CD4C/HIV transgenic mice shows impaired germinal centers and autoantibodies and develops in the absence of IFN-gammaandIL-6. Immunity. 2001;15:173-185.
64. Chong Y, Ikematsu H, Yamamoto M, et al. Increased frequency of CD27- (naive) B cells and their phenotypic alteration in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2004;20:621-629.
65. Rosenberg YJ, Lewis MG, Greenhouse JJ, et al. Enhanced follicular dendritic cell function in lymph nodes of simian immunodeficiency virus-infected macaques: consequences for pathogenesis. Eur J. Immunol. 1997;27:3214-3222.
66. Rosenberg YJ, Lewis MG, Kosco-Vilbois MH. Enhanced follicular dendritic cell-B cell interaction in HIV and SIV infections and its potential role in polyclonal B cell activation. Dev Immunol. 1998;6:61-70.
67. Fondere JM, Huguet MF, Yssel H, et al. Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy. AIDS. 2003;17:2323-2330.
68. Fondere JM, Huguet MF, Macura-Biegun A, et al. Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:114-119.
69. Edghill-Smith Y, Bray M, Whitehouse CA, et al. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis. 2005;191:372-381.
70. Agematsu K, Nagumo H, Shinozaki K, et al. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J Clin Invest. 1998;102:853-860.
71. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol. 2003;3:822-829.
72. Devito C, Zuber B, Schroder U, et al. Intranasal HIV-1-gp 160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol. 2004;173:7078-7089.
73. Edelman AS, Zolla-Pazner S. AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency. FASEB J. 1989;3:22-30.